Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efavirenz in Alzheimer's Disease
NCT03706885Phase 1Completed
- Sponsor
- Case Western Reserve University
- Start
- May 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of efavirenz in Alzheimer's disease (AD) (3 arms), sponsored by Case Western Reserve University. Primary endpoints: Plasma levels of 24-hydroxycholesterol at 20 weeks and Safety and tolerability of efavirenz at 20 weeks. Started May 2018; status: completed.
02
Drugs
efavirenz
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03706885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03706885.